Bio Rad Laboratories Inc
NYSE:BIO
P/FCFE
Price to FCFE
Price to Free Cash Flow To Equity (P/FCFE) ratio is a valuation multiple that compares a company’s market capitalization to the amount of free cash flow available for equity shareholders. This metric is very similar to the P/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.
Market Cap | P/FCFE | ||||
---|---|---|---|---|---|
US |
Bio Rad Laboratories Inc
NYSE:BIO
|
8.4B USD | 38.1 | ||
US |
Thermo Fisher Scientific Inc
NYSE:TMO
|
229.6B USD | 42.1 | ||
US |
Danaher Corp
NYSE:DHR
|
191.9B USD | 51.7 | ||
US |
Agilent Technologies Inc
NYSE:A
|
44.3B USD | 38.6 | ||
US |
IQVIA Holdings Inc
NYSE:IQV
|
41.7B USD | 23.4 | ||
KR |
Samsung Biologics Co Ltd
KRX:207940
|
55.6T KRW | -452.1 | ||
CH |
Lonza Group AG
SIX:LONN
|
36.7B CHF | 133.5 | ||
US |
Mettler-Toledo International Inc
NYSE:MTD
|
32B USD | 37.1 | ||
IE |
ICON PLC
NASDAQ:ICLR
|
26B USD | 155.9 | ||
US |
West Pharmaceutical Services Inc
NYSE:WST
|
25.9B USD | 67.4 | ||
US |
Waters Corp
NYSE:WAT
|
21.4B USD | 19.6 |
P/FCFE Forward Multiples
Forward P/FCFE multiple is a version of the P/FCFE ratio that uses forecasted free cash flow to equity for the P/FCFE calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to equity forecasts for 1, 2, and 3 years ahead, respectively.